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Significance Statement 
The repair of damaged cartilage with engineered tissues may be hampered by challenges 
stemming from the need to provide appropriate environmental cues to progenitor cells. By 
chemically targeting the Hypoxia Inducible Factor complex to mimic the effects of hypoxia, 
we show that the 2-oxoglutarate (2-OG) analogue DMOG induces HIF signalling and a more 
articular chondrocyte-like expression profile in human BM-MSC compared to CoCl2 or DFX, 
which reduce Fe2+ bioavailability. These observations suggest that human BM-MSC may rely 
more on mechanisms that utilise 2-OG than Fe2+ during chondrogenesis and suggest that 
DMOG could be effective therapeutically for cartilage regeneration.  
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Abstract 
The transcriptional profile induced by hypoxia plays important roles in the chondrogenic 
differentiation of marrow stromal/stem cells (MSC) and is mediated by the Hypoxia 
Inducible Factor complex. However, various compounds can also stabilise HIF’s oxygen-
responsive element, HIF-1α, at normoxia and mimic many hypoxia-induced cellular 
responses. Such compounds may prove efficacious in cartilage tissue engineering, where 
microenvironmental cues may mediate functional tissue formation. Here, we investigated 
three HIF stabilising compounds, which each have distinct mechanisms of action, to 
understand how they differentially influenced the chondrogenesis of human bone marrow-
derived MSC (hBM-MSC) in vitro. hBM-MSCs were chondrogenically-induced in TGF-β3-
containing media in the presence of HIF-stabilising compounds. HIF-1α stabilisation was 
assessed by HIF-1α immunofluorescence staining, expression of HIF target and articular 
chondrocyte specific genes by qPCR, and cartilage-like extracellular matrix (ECM) 
production by immunofluorescence and histochemical staining. We demonstrate that all three 
compounds induced similar levels of HIF-1α nuclear localisation. However, whilst the 2-
oxoglutarate analogue Dimethyloxalylglycine (DMOG) promoted upregulation of a selection 
of HIF target genes, Desferrioxamine (DFX) and Cobalt Chloride (CoCl2), compounds that 
chelate or compete with Fe2+, respectively, did not. Moreover, DMOG induced a more 
chondrogenic transcriptional profile, which was abolished by Acriflavine, an inhibitor of 
HIF-1α-HIF-β binding, whilst the chondrogenic effects of DFX and CoCl2 were more 
limited. Together, these data suggest that HIF-1α function during hBM-MSC chondrogenesis 
may be regulated by mechanisms with a greater dependence on 2-oxoglutarate than Fe2+ 
availability. These results may have important implications for understanding cartilage 
disease and developing targeted therapies for cartilage repair. 
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Abbreviations 
 
2-Oxoglutarate (2-OG) 
Acriflavine (ACF) 
Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) 
Chondrogenic Differentiation Media (CDM) 
Cobalt Chloride (CoCl2) 
Collagen Prolyl Hydroxylase (CP4HA1) 
Desferrioxamine (DFX) 
Dimethyloxalylglycine (DMOG) 
Divalent iron (Fe2+) 
Double stranded Deoxyribonucleic Acid (dsDNA) 
Extracellular Matrix (ECM) 
Factor Inhibiting Hypoxia Inducible Factor (FIH) 
Foetal Bovine Serum (FBS) 
Glycosaminoglycans (GAGs) 
Growth Media (GM) 
Hypoxia Inducible Factor (HIF) 
Mesenchymal Stem Cells (MSCs) 
Messenger Ribonucleic Acid (mRNA) 
Oxygen (O2) 
Prolyl Hydroxylase 2 (PHD2) 
Quantitative Polymerase Chain Reaction (qPCR) 
Room Temperature (RT) 
Transforming Growth Factor-β (TGF-β)  
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Introduction 
Acute lesions to the articular cartilage that do not heal may be painful and can progress to 
osteoarthritis. Conventional treatments such as microfracture or articular chondrocyte 
implantation are not always effective in mediating repair [1, 2]. Tissue engineering strategies 
that combine cells with bioactive factors and biomaterial scaffolds may allow for de novo 
articular cartilage formation and provide an alternative therapy for patients [3-5]. However, 
the provision of cues that can appropriately direct progenitor cell differentiation and tissue 
formation remain a challenge.  
One of the regulatory factors controlling articular cartilage development is the cellular 
response to physiological hypoxia [6, 7]. The cellular response to hypoxia is mediated by the 
hypoxia inducible factor [8] pathway which induces expression of hypoxia-responsive genes 
[9]. At normoxia, the HIF complex is unable to recruit the oxygen-responsive HIF-1α 
subunit, which inhibits expression of genes containing a HIF response element within their 
promoter regions [10]. Under hypoxic conditions, HIF-1α translocates to the nucleus where it 
complexes with other components of the HIF complex to initiate transcription of HIF target 
genes [10]. HIF-1α is central in the formation of articular cartilage during development [6, 7]. 
It also plays essential roles in the differentiation of mesenchymal stem/stromal cells (MSC) 
[11, 12] and chondroprogenitors [13] into cells capable of producing cartilage-like 
extracellular matrix (ECM) [14-16]. Moreover, HIF-1α is vital in maintaining the articular 
phenotype of differentiated chondrocytes and inhibiting hypertrophic differentiation [17].  
Two hydroxylases, prolyl hydroxylase 2 (PHD2) and factor inhibiting HIF (FIH), regulate the 
participation of HIF-1α in the HIF complex [18, 19]. Each catalyses the hydroxylation of 
specific residues on HIF-1α by utilising molecular oxygen (O2) as a substrate together with 
ascorbic acid, iron (Fe2+) and 2-oxoglutarate (2-OG). PHD2-mediated proline hydroxylation 
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results in ubiquitination of HIF-1α and its subsequent proteasomal degradation, whereas 
asparagine hydroxylation by FIH prevents HIF-1α from binding to the co-factor, p300 in the 
HIF complex [18]. Under hypoxic conditions, the lack of oxygen reduces PHD2 and FIH 
activity, enabling HIF-1α to accumulate in the nucleus and form an active transcriptional 
complex with co-factors at the promoter regions of HIF target genes.  
The importance of hypoxia and HIF in cartilage development and maintenance point towards 
its potential utility in cartilage tissue engineering strategies. Indeed, chemical agents that 
upregulate HIF have been shown to drive the chondrogenic differentiation of MSC and 
promote articular chondrocytes to produce a cartilage-like ECM [12, 20, 21]. However, 
studies which compare the efficacy of different HIF-stimulating compounds in driving the 
chondrogenesis of hBM-MSC compared to standard protocols which utilise transforming 
growth factor-β (TGF-β), are lacking.  
Therefore, we compared the effects of three hydroxylase inhibitors on the chondrogenic 
differentiation of hBM-MSC. Dimethyloxalylglycine (DMOG) strongly binds to the 2-OG 
binding pocket of both FIH and PHD2, acting as a competitive inhibitor [22]; 
Desferrioxamine (DFX) sequesters intracellular Fe2+, which is required by FIH and PHD2 
[23], and thereby reduces their activity; and Cobalt Chloride (CoCl2) competes with Fe2+ by 
directly binding to the PHD2 active site [24]. We chose these agents because they cover the 
main classes of HIF-stimulating compounds, and as such, upregulate HIF-1α via distinct 
mechanisms (Figure 1A+1B). These compounds are also the most widely studied for 
chemically regulating HIF and may shed light on key regulatory elements of hypoxic 
signalling during chondrogenesis. Moreover, investigating the PHD2/FIH inhibitors during 
hBM-MSC chondrogenesis may aid our understanding of the pathophysiology of 
degenerative diseases such as osteoarthritis [8], for which HIF-1α is known to play a 
protective role [25]. 
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Here, we show that whilst CoCl2, DFX and DMOG all induce similar levels of HIF-1α 
stabilisation, only DMOG strongly enhances HIF-mediated transcription of key chondrogenic 
genes. Nevertheless, DMOG negatively impacted the production of Collagen Type II and 
glycosaminoglycans (GAGs), which could be alleviated by only exposing cells to the 
compound during the latter stages of chondrogenesis. Together, these observations highlight 
the potential importance of mechanisms which utilise 2-OG compared to Fe2+ for the 
transcriptional control of HIF target genes during hBM-MSC chondrogenesis. They also 
suggest that 2-OG inhibitors may better promote a chondrogenic transcriptome compared to 
either DFX or CoCl2. These observations may inform on improved, targeted strategies for 
stimulating cartilage ECM formation in tissue engineering-based therapies. 
 
Materials & Methods 
Isolation and expansion of hBM-MSC 
hBM-MSCs were isolated from bone marrow aspirates collected from the iliac crest of 
healthy paediatric donors, with informed consent from their parents or guardians. Cells were 
seeded in CellSTACK® (Corning) culture chambers at 10-25x106/636 cm2 and cultured in 
αMEM supplemented with human platelet lysate (Stemulate, Cook Medical, USA). At 90-
100% confluency, cells were passaged and seeded at 5000 cells/cm2. For 
immunophenotyping of hBM-MSCs, the following antibodies were used in conjunction with 
a FACSCalibur™ analyser (BD Biosciences): CD90-FITC, CD105-APC, CD73-PE, CD34-
PE, and CD45-FITC (all from BD Biosciences). All human tissue was approved for use by 
the UK National Research Ethics Service (12/WA/0196) and was collected by the National 
Institute for Health Research, which is supported by the Imperial College Healthcare Tissue 
Bank (HTA license 12275). Cultures were found to express CD90, CD105, CD73 and not 
express hematopoietic markers CD34 and CD45 [26] (data not shown). hBM-MSCs were 
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expanded in growth media (GM; αMEM + 10% Foetal Bovine Serum (FBS)) under standard 
conditions (5% CO2).  
 
Chondrogenic Induction of hBM-MSC  
hBM-MSCs were expanded to passage 5 in GM under standard culture conditions before 
cryopreservation in a solution composed of 10% Dimethyl Sulfoxide, 40% FBS and 50% 
GM. Cells were stored in liquid nitrogen prior to use. For chondrogenic induction 
experiments, cryovials of hBM-MSCs were thawed in GM and grown to confluence before 
plating at 3x104/cm2 into multi-well tissue culture plates. Cultures were incubated for 24 h in 
GM prior to induction using standard chondrogenic differentiation media (CDM). See Figure 
1C for experimental plan. Cells were differentiated as monolayers to prevent the formation of 
a local hypoxic microenvironment independent of experimental conditions (physiological or 
chemically-induced hypoxia). Indeed, whilst pellet/micromass cultures may be more 
conducive for chondrogenesis, the bioavailability of oxygen may vary between cells at the 
periphery and centre of such cultures. CDM consisted of High Glucose Dulbecco's Modified 
Eagle Medium (Sigma Aldrich) + 2mM L-Glutamine (Thermo Fisher Scientific) + 100nM 
Dexamethasome (Sigma Aldrich) + 1% Insulin, Transferrin, Selenium Solution (Thermo 
Fisher Scientific) + 1% Antibiotic Antimycotic solution (Sigma Aldrich) + 50μg/ml Ascorbic 
acid-2-phosphate (Sigma Aldrich) + 40μg/ml L-proline (Sigma Aldrich) + 10ng/ml TGF-β3 
(Peprotech). CDM was supplemented with HIF-stabilising compounds (Sigma Aldrich): 
100μM CoCl2, 50μM DFX and 200μM DMOG, or incubated in un-supplemented CDM at 
hypoxia (5%O2) or normoxia. To achieve HIF-1α inhibition, media was further supplemented 
with 500nM Acriflavine (ACF; Santa Cruz).  
 
Neutral Red Viability Assay 
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Neutral red dye (Sigma-Aldrich) dissolved in cell culture medium was incubated with 
differentiating hBM-MSC for 2 h before fixation in 0.1% Calcium Chloride+0.5% 
paraformaldehyde. Dye retained by hBM-MSC was solubilised in 1% acetic acid + 50% 
ethanol. Quantification of solubilised Neutral Red was then performed on an absorbance 
spectrophotometer at 540nm. 
 
PicoGreen Assay  
Samples were snap-frozen at -80 °C and digested in 400μg/ml Papain Buffer at 65 °C for 18 
hours. Double stranded Deoxyribonucleic Acid (dsDNA) content in papain-digested cultures 
was quantified using a PicoGreen kit (Thermo Fisher Scientific). A linear relationship was 
observed between hBM-MSC number and dsDNA content. 
 
SDS-PAGE & Western Blotting 
Following 24-hours of culture, cells were lysed in Sodium Dodecyl Sulfate (SDS) buffer and 
protein was quantified using a Bicinchoninic Acid assay (Thermo Fisher Scientific). Lysates 
were run on polyacrylmide gels (Biorad) and transferred using the Trans-Blot Turbo Transfer 
System (Biorad). HIF-1α and housekeeping protein β-Actin were bound by primary 
antibodies (h-206; Santa Cruz and ab8227; Abcam). Signal detection produced between a 
horseradish peroxidase-conjugated secondary antibody (sc-2004; Santa Cruz) and the 
Chemiluminescent ECL substrate (Biorad) were detected on a Chemidoc Touch imaging 
platform (Biorad). HIF-1α and protein levels were generated by densitometric analysis with 
ImageJ and normalised to that of β-Actin.  
 
Quantitative Polymerase Chain Reaction  
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RNA was extracted using the RNeasy Mini Kit (Qiagen). 100ng of RNA per sample was 
reverse transcribed using M-MLV Reverse Transcriptase (Promega) and cDNA was 
amplified using quantitative polymerase chain reactions (qPCR) in a CFX384 (Biorad). 
Brilliant III Ultra-Fast SYBR® Green QPCR Master Mix (Agilent) was used in conjunction 
with primers specific to genes of interest. Primer sequences are shown in Supplemental Table 
1. All primers produced a linear relationship between template concentration and Ct value. 
Reaction efficiencies were confirmed to always be between 90 and 110%. Raw Ct values 
were converted to transcript copy number by the relative standard curve method of analysis, 
and expression levels were normalised to that of RPL13A. Following normalisation to the 
housekeeping gene, expression levels were then normalised to that of the untreated control to 
determine fold change in expression induced by each treatment. 
 
Immunofluorescence Staining  
Cultures were fixed in 4% (w/v) paraformaldehyde for 15 minutes. HIF-1α and Collagen 
Type II were then detected using h-206 (Santa Cruz) and ab34712 (Abcam) (respectively), 
overnight, following blocking with (10%) goat serum (Sigma Aldrich) for 60 min and 
permeabilisation in 0.1% (v/v) Triton X-100 solution (Sigma Aldrich) for 60 min, both at 
room temperature (RT). Collagen Type X was detected using ab49945 (Abcam) at a 1:250 
dilution overnight. Rabbit-derived primary antibodies were visualised with ab150077 
(Abcam) after staining for 60 min at RT at dilutions of 1:000 and 1:200 for Collagen Type II 
and HIF-1α, respectively. Mouse-derived primary antibodies were detected with biotin 
(ab6788, Abcam) and Streptavidin (S11223, Thermo Fisher Scientific) both at 1:350 for 60 
min. Cultures were counterstained with 0.1μg/ml DAPI for 60 min to visualise nuclei and 
fluorescence was imaged on an Axiovert200M microscope (Zeiss). The images in 
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Supplemental Figure 1 confirm that signal was due to each primary antibody and not 
background fluorescence or non-specific binding of the secondary antibody. 
 
Alcian Blue Staining 
4% paraformaldehyde-fixed cultures were stained with 1% Alcian Blue solution, pH 1.0 
(Sigma Aldrich) prepared in 0.1N HCl. Haematoxylin (Vector Laboratories) was used to 
visualise cell nuclei and staining was imaged on an Axiovert200M microscope (Zeiss).  
 
Glycosaminoglycan Quantification 
At day 21 of chondrogenesis, cultures were washed in PBS and frozen at -80 °C before 
their digestion in 400μg/ml Papain buffer (Sigma Aldrich) supplemented with 0.2M Sodium 
Phosphate + 5mM Ethylenediaminetetraacetic acid + 5mM L-Cysteine (all Sigma Aldrich) at 
65 °C for 18 h. Glycosaminoglycans were quantified from Papain-digested lysates using the 
GAG assay kit by Blyscan™  in which GAGs were dyed with 1,9-dimethyl-methylene blue 
and subsequently dissociated with Propan-1-ol solution before quantification on an 
absorbance spectrophotometre at 640nm. Values were normalised to levels of dsDNA, which 
were quantified using the PicoGreen assay. 
 
Immunofluorescence Quantification 
Immunofluorescence images were captured using identical gain, exposure and offset for all 
conditions in each experiment. These were determined with positive controls that expressed 
the antigen of interest, and negative controls in which the primary antibody was omitted 
(Supplemental Fig. 1). The same threshold fluorescence intensity for images of all conditions 
within an experiment was set, below which the signal produced was negated as background. 
The signal produced above the threshold was regarded as bona fide protein detection and was 
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used to create a binary representation of each image. The percentage of immunofluorescence 
staining present within a specified area was then determined. 
 
Statistical Analysis 
All statistical analyses were performed in Prism7 (GraphPad) with the Mann-Whitney test 
used to compare two conditions and Kruskal-Wallis with Dunn’s Correction for multiple 
condition comparisons. Non-parametric tests were used as we were unable to demonstrate 
normality in all datasets. *marks all differences that were statistically significant (p<0.05). 
  
Results 
 
Hypoxia promotes HIF stabilisation and a more articular cartilage-like cell phenotype 
It is well established that hBM-MSCs can be chondrogenically differentiated with 
transforming growth factor β3 (TGF-β3) ligands. Therefore, we first aimed to determine if 
chondrogenesis could be further enhanced by culture under hypoxic conditions, as previously 
reported [11]. Hypoxia increased messenger Ribonucleic Acid (mRNA) expression of a 
selection of known HIF target genes including VEGFA, EGLN, and PGK1 (all p=0.0286) 
[27-29] compared to that in hBM-MSC cultured under normoxic conditions (Figure 2A). 
These observations were in line with previous studies which have similarly shown a rapid (24 
h) upregulation of HIF and HIF-mediated transcription in response to hypoxia under 
chondrogenic conditions [11]. However, 5%O2 did not significantly affect expression of 
SOX9 (Figures 2A+2B; p=0.1), the master transcriptional regulator of chondrogenesis [30], 
after either 1 or 14 days in culture.  
At day 14 we observed upregulation of expression of the gene for the articular cartilage ECM 
component Collagen Type II (COL2A1, p=0.0002), and downregulation of the hypertrophic 
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marker Collagen Type X [31] (COL10A1, p=0.0006) under hypoxic conditions compared to 
that at normoxia (Figure 2B). COL2A1 and COL10A1 are targets of transcription factors 
SOX9 and RUNX2, respectively, and are known to be regulated as the chondrogenic 
differentiation of MSC proceeds [11]. Culture for 21 days under hypoxic conditions did not 
affect cell viability or proliferation (Figure 2C). However, as expected, we did observe 
increased HIF-1α nuclear localisation (p<0.0001) in hypoxic compared to normoxic cultures 
(Figures 2D-2H). Hypoxia also increased Alcian Blue staining of GAGs (Figures 2I+2J), but 
did not affect the immuno-detection of Collagen Type II protein (Figures 2K+2L). 
Nevertheless, we did detect a decrease in staining for Collagen Type X (Figures 2M+2N), 
consistent with hypoxia’s inhibitory role to chondrocyte hypertrophy [17]. Together, these 
observations confirmed that culture under hypoxic conditions in the presence of TGF-β3 
promoted an articular chondrocyte-like phenotype that was conducive for articular cartilage 
ECM rather than hypertrophic cartilage formation. This effect appeared to not require a 
corresponding upregulation of SOX9, but instead correlated with increased immunostaining 
for HIF-1α, upregulation of select HIF target genes VEGFA, EGLN, and PGK1, and increased 
HIF-1α nuclear localisation. 
 
CoCl2, DFX and DMOG induce HIF-1α localisation, but only DMOG strongly 
upregulates HIF targets VEGFA, PGK1 and ELGN 
Having determined that hypoxia promoted HIF-1α stabilisation and expression of VEGFA, 
EGLN, and PGK1, we next aimed to determine if inhibitors of the hydroxylases PHD2 and FIH 
would have a similar effect on hBM-MSC cultured under normoxic conditions. We first 
determined appropriate doses for the hydroxylase inhibitors DMOG, DFX and CoCl2 by 
confirming that concentrations of each used extensively in the literature [22, 24, 32-34] were 
non-toxic to hBM-MSC over 21 days of chondrogenic differentiation (Supplementary Figures 
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2 and 3). Next, we confirmed that each could stabilise HIF by carrying out Western blots for 
HIF-1α in whole-cell lysates after 24 h, as HIF is known to be rapidly induced in response to 
PHD2/FIH inhibition [22]. Levels of HIF-1α protein were significantly increased in cells 
cultured under hypoxic conditions (p=0.0286); however, despite trends for increased levels of 
HIF-1α after treatment with HIF stabilising compounds, we failed to detect statistically 
significant differences (p=0.314) compared to controls (Figures 3A+3B). Nonetheless, nuclear 
localisation of HIF-1α was enhanced compared to controls (p=<0.0001) in response to 
treatment with all three compounds (Figures 3C-3K).  
We then examined the effects of the hydroxylase inhibitors on HIF target gene expression. 
DMOG significantly and consistently upregulated expression of VEGFA (p= day 1: 0.0073, 
day 7: 0.0470, day 21: 0.0005), PGK1 (p= day 1: 0.0073, day 7: 0.0013, day 14: 0.0013, day 
21: 0.0031) and EGLN (p= day 1: 0.0108, day 7: 0.0332, day 14: 0.0470, day 21: 0.0005) 
(Figures 3L-3N). However, the effects of CoCl2 and DFX were more subtle, and we only 
observed upregulation of PGK1 expression at day 14 (p=0.0391) and EGLN at day 21 
(p=0.0396) in response to DFX. These observations show that whilst CoCl2, DFX, and 
DMOG all affect HIF-1α stabilisation, only DMOG strongly upregulated expression of a 
selection of HIF target genes. This suggests that DMOG more potently enhanced HIF activity 
compared to DFX or CoCl2.  
 
DMOG stimulates hBM-MSC to adopt an articular chondrocyte-like transcriptional 
profile  
As all HIF mimetics stabilised HIF-1α and DMOG also upregulated expression of HIF target 
genes, we next investigated the effect of these compounds on chondrogenic gene expression. 
DMOG treatment upregulated SOX9 mRNA after 7 (p=0.0159) and 21 (p=0.0332) days in 
culture (Figure 4A), whilst RUNX2, a key regulator of osteogenesis [35], was unaffected 
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under all conditions (Figure 4B). This resulted in a DMOG-mediated increase in the SOX9 to 
RUNX2 expression ratio throughout differentiation (Figure 4C; p= day 7: 0.0192, day 14: 
0.0398, day 21: 0.0159). All inhibitors upregulated expression of COL2A1 (Figure 4D; p= 
CoCl2: 0.0280, DFX: 0.0180, DMOG: 0.0008) with DMOG significantly downregulating 
COL10A1 (Figure 4E; p=0.0037) leading to an increased COL2A1/COL10A1 mRNA ratio 
due to DFX and DMOG (Figure 4F; p= DFX: 0.0259, DMOG: <0.0001). ACAN, which 
encodes the gene for Aggrecan, the most abundant proteoglycan in cartilage [36], was not 
upregulated by any treatment (Figure 4G); and MMP13, which contributes to an osteoarthritic 
chondrocyte phenotype [37], was similarly unaffected (Figure 4H). The articular cartilage 
phenotype is marked by appropriate post-translational modifications of secreted collagen by 
enzymes encoded by P4HA1 and LOX [14, 15]. DMOG strongly upregulated both P4HA1 
(Figure 4I; p=0.0039) and LOX (Figure 4J; p=0.0027) expression, whilst DFX only 
upregulated LOX (p=0.0056) and CoCl2 had no significant effects. Taken together, these 
observations demonstrate that DMOG upregulated transcriptional regulators of 
chondrogenesis and genes involved in cartilage ECM formation, whilst the effects of CoCl2 
and DFX were more limited. 
 
DMOG inhibits incorporation of Collagen Type II, Type X and GAGs into the cell-
secreted ECM 
As treatment with DMOG regulated the expression of genes associated with a chondrocyte 
phenotype, we next asked if this influenced cartilage-like matrix formation. In line with 
changes in gene expression, hBM-MSC treated with DMOG for 21 days showed little to no 
staining for Collagen Type X compared to controls (Figures 5A+5D). We observed a similar 
effect in both DFX- and CoCl2-treated cultures (Figures 5B+5C). However, whilst CoCl2- 
and DFX-treated cultures showed similar levels of staining for Collagen Type II as controls 
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(Figures 5E-5G), DMOG-treated cultures showed only sparse staining (Figure 5H). This was 
confirmed by quantification of Collagen Type II immunofluorescence both without 
(p=0.0286) and with normalisation to cell number which indicated reduced Collagen Type II 
production per cell (Figure 5M; p=0.0286). Alcian blue staining confirmed these observations 
as DMOG-treated cultures showed fewer GAG-positive areas than the other groups, although 
quantitative differences in staining on a per cell basis were not significant (Figures 5I-
5L+5N). Overall, DMOG appeared to reduce the total amount of cartilage-like ECM that 
cells formed in their immediate extracellular space.  
 
HIF-1α mediates DMOG’s induction of an articular chondrocyte transcriptional profile  
As DMOG mediated antithetical effects in terms of chondrogenic transcriptional profile and 
ECM formation, we next aimed to study its mechanism of action. To accomplish this, we 
supplemented CoCl2/DFX/DMOG-containing CDM with Acriflavine (ACF), an inhibitor of 
HIF-1α and HIF-1β binding [38]. ACF abolished the DMOG-induced upregulation of 
established HIF targets, but did not affect total cell number during chondrogenesis 
(Supplemental Figure 4A and Supplemental Figure 4B). Staining for Collagen Type II in 
DMOG-treated cultures supplemented with ACF remained sparse (Figures 6A-6C), but 
quantitative image analyses showed staining on a per cell basis was no different from 
controls, whilst cultures treated with DMOG alone were significantly lower (Figure 6D; 
p=0.0076). This suggests that the inhibitory role of DMOG on Collagen Type II matrix 
formation may be partly mediated through HIF-1α activity.  
We next asked if DMOG’s stimulation of the chondrogenic transcription profile in hBM-
MSC was also mediated through HIF-1α. ACF abrogated DMOG-mediated changes in 
expression of HIF targets, VEGFA (Figures 6E; p= -ACF: 0.0132, +ACF: 0.0772) and EGLN 
(Figures 6F; p= -ACF: 0.0073, +ACF: 0.1232), COL2A1 (Figure 6H; p= -ACF: 0.0286, 
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+ACF: >0.999), COL10A1 (Figure 6I; p= -ACF: 0.002, +ACF: >0.3277), the 
COL2A1/COL10A1 ratio (Figure 6J; p= -ACF: 0.0031, +ACF: >05998), and showed a similar 
trend for SOX9 expression (Figure 6G; p= -ACF: 0.0772, +ACF: 0.5348) Interestingly, 
despite a lack of upregulation of SOX9 under hypoxic conditions, we observed a negative 
effect of hypoxia on SOX9 expression in the presence of ACF (Figure 6G; p= 0.0286). This is 
consistent with the observation that ACF reduced the ratio of COL2A1/COL10A1 under 
hypoxic conditions (Figure 6J; p=0.0286) and suggests that hypoxia, via HIF-1α, does indeed 
regulate basal levels of chondrogenic targets genes, such as SOX9. Overall, these data suggest 
that HIF-1α mediated DMOG’s effect on the transcriptional profile of chondrogenically 
induced hBM-MSC. Moreover, ACF appeared to have a larger effect on DMOG-mediated 
transcription than that induced by either CoCl2 or DFX (Supplemental Figure 4C-4J).   
 
Late DMOG treatment enhances chondrogenesis  
As DMOG upregulated chondrogenic transcripts but continuous treatment led to reduced 
staining for cartilage-like matrix, we next asked if altering either the length/timing of 
treatment would influence ECM formation. Therefore, we next treated hBM-MSC with 
DMOG, DFX and CoCl2 either continuously (as before) or during late (days 14-21) time 
periods and analysed mRNA and protein expression of ECM markers after 21 days. Late 
DMOG treatment did not negatively affect the secretion of Collagen Type II compared to 
controls (p=0.282), as we observed with continuous DMOG treatment (p=0.0188). This 
contrasted with treatment with either DFX or CoCl2, where both continuous and late 
treatment had no effect on Collagen Type II secretion (p=>0.9999 for both, Figure 7A-7H). 
At the mRNA level, like continuous treatment (p=0.0023), late exposure to DMOG induced 
significant upregulation of SOX9 (Figure 7I; p=0.0168). Late DMOG also upregulated 
expression of P4HA1 (Figure 7J; p=0.0286), and HIF targets VEGFA (p=0.0358, Figure 7K) 
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and EGLN (p=0.0208, Figure 7L) as with continuous DMOG treatment (p= P4HA1: 0.0313, 
VEGFA: 0.0118, EGLN: 0.0088). In contrast, neither continuous nor late CoCl2 and DFX 
treatment significantly affected the expression of these genes, with the exception of 
continuous DFX treatment on SOX9 (p= 0.0286; Figure 7I) and P4HA1 (p= 0.0286; Figure 
7J). Taken together, late treatment with DMOG induced a similar expression profile to 
continuous treatment, but without negatively impacting the formation of cartilage-like ECM. 
 
Discussion 
Hypoxic conditions are known to favour articular cartilage development. The pro-
chondrogenic effects of hypoxia are thought to be mediated primarily through HIF-1α via the 
formation of a transcriptionally-active complex at target genes [7, 12]. Therefore, we and 
others hypothesised that compounds that increase HIF-1α availability would promote HIF-
mediated chondrogenesis. Previous studies have examined the effect of CoCl2 [12], DFX [39] 
and DMOG [21, 40] in this context. Whilst such studies have cemented the role of HIF-1α in 
chondrogenesis, to our knowledge no study has yet examined their comparative effects 
during cartilage formation or the chondrogenic differentiation of precursors. As the inhibitors 
have differential mechanisms of action, comparatively studying their effects may have 
important implications for HIF biology and cartilage regenerative medicine. Indeed, instead 
of utilising physiological hypoxia for regenerative medicine, stabilising the HIF complex 
under normoxic conditions would remove the complex logistics required for spatial 
organisation of oxygen. This may be particularly valuable in engineering constructs for the 
repair of full osteochondral defects due to the contrasting oxygen requirements of avascular 
cartilage and vascularised bone [6]. HIF mimetics could also potentially avoid the 
undesirable HIF-independent effects of hypoxia such as the unfolded protein response and 
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associated cell stress [41], and could preclude the development of a tolerance to the reduced 
oxygen levels [42, 43].  
In our control conditions, we defined hypoxia as 5%O2 to balance its well-described pro-
chondrogenic effects against its negative impacts on cell viability [44]. As expected, after 24 
h in culture under hypoxic conditions, we detected upregulation of HIF target genes, as others 
have described [19, 45], as well as increased expression of SOX9 target COL2A1 and 
downregulation COL10A1 (day 14). We also detected an increase in staining for GAGs and 
reduced Collagen Type X protein formation. Surprisingly, upregulation of SOX9 was not 
maintained throughout the 21-day differentiation. This is in keeping with previous reports 
that continued upregulation of SOX9 expression in mouse MSC under hypoxic conditions 
does not correlate with upregulation of its target genes [11]. We also observed that SOX9 
expression was downregulated in the presence of ACF, perhaps suggesting that hBM-MSC 
cultures do rely on HIF for physiological hypoxia’s downstream effects. Indeed, cells may 
develop a tolerance to hypoxia following the initial induction [43], and during long-term 
culture, hypoxia may act to maintain basal levels of expression of chondrogenic genes.  
One of our most striking observations was the ability of DMOG, via HIF-1α, to induce hBM-
MSC to upregulate expression of HIF target genes and chondrogenic transcripts, and 
downregulate mRNA encoding hypertrophic chondrocyte markers such as Collagen Type X. 
In comparison, neither CoCl2 nor DFX stimulated similar changes, despite their ability to 
promote HIF-1α nuclear localisation. The stability and nuclear localisation of HIF-1α is 
controlled by PHD2, whereas HIF-1α co-factor binding is controlled by FIH; DMOG has 
been shown to inhibit both hydroxylases [22]. This is unlike the effect of iron chelators which 
target PHD2, but do not inhibit FIH as potently [24]. Others have shown that FIH requires 
higher levels of 2-OG than PHD2 to achieve the same levels of enzymatic activity [46], 
which may suggest an increased sensitivity of FIH than PHD2 to inhibition by 2-OG 
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analogues. HIF-1α activity in hBM-MSC may also be more dependent on FIH inhibition, 
rather than PHD2, as high levels of HIF-1α mRNA have been observed in these cells [42]. 
Indeed, high levels of HIF-1α transcription might compensate for decreases in HIF-1α 
stability due to PHD2-mediated hydroxylation. Taken together, these observations suggest 
that regulation of HIF-mediated transcription that is conducive for hBM-MSC articular 
chondrogenesis, is dependant more on 2-OG-mediated mechanisms than those controlled by 
intracellular Fe2+ levels. Additionally, previous studies which demonstrate the dependence of 
FIH on 2-OG availability and the ability of DMOG to inhibit both PHD2 and FIH, suggest 
that DMOG’s potent effect here may be via inhibition of both hydroxylases, whereas CoCl2 
and DFX may inhibit PHD2 only.  
The ability of DMOG to induce an expression profile that is conducive for articular 
chondrogenesis, suggests its advantage over CoCl2 and DFX for use in cartilage-regenerative 
therapies. However, despite inducing expression of COL2A1 and genes involved in post-
translational modifications of collagen, DMOG had a negative effect on cartilage-like ECM 
production. We showed that this was partly mediated via HIF-1α, however, other 
mechanisms are likely involved as we were unable to completely rescue cartilage-like ECM 
formation with Acriflavine. DMOG has been shown to reduce the activity of prolyl-4-
hydroxylase, which is required for correct folding and polymerisation of collagen fibrils [21]. 
Correspondingly, both FIH and Collagen Prolyl Hydroxylase (P4HA1) have similar affinities 
for 2-OG, as they have similar Km values for this co-factor [47]. Therefore, FIH and P4HA1 
are likely equally sensitive to DMOG. This suggests that DMOG-mediated upregulation of 
HIF target genes via FIH inhibition might be accompanied by a similarly potent inhibition of 
collagen processing and incorporation into the ECM. Treatment with DMOG for the final 7 
days of induction restored the reduced levels of Collagen Type II whilst upregulating 
expression of HIF target and chondrogenic genes to similar levels we observed in response to 
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continuous treatment. This response could have been mediated by a lack of continuous 
inhibition of the collagen prolyl hydroxylase. Taken together, late DMOG treatment, which 
can stimulate the formation of appropriate ECM, and induce mRNA expression of genes 
similarly to continuous treatment, may be a valuable strategy for cartilage regenerative 
medicine.  
 
Conclusion 
Hydroxylase inhibitors are potentially valuable in cartilage tissue engineering strategies as 
they can mimic many of the effects of hypoxia, providing important environmental cues to 
progenitors, but without many of its potential drawbacks. Here, we show that CoCl2, DFX 
and DMOG treatment all induced HIF-1α stabilisation. However, unlike CoCl2 and DFX, 
DMOG treatment strongly regulated HIF targets, and promoted chondrocyte-specific gene 
expression. This suggests that in hBM-MSC undergoing chondrogenic differentiation, HIF-
mediated changes in gene expression may rely more on mechanisms that utilise 2-OG than 
those that rely on Fe2+. Our observations also suggest a role for DMOG in cartilage tissue 
engineering strategies. For example, scaffolds that spatially and/or temporally control the 
release of DMOG could target the articular cartilage to aid in the repair of focal defects. 
However, the maintenance of cartilage ECM in late treatment-only conditions suggests the 
use of this 2-OG analogue would need to be optimised with regards to dosage/treatment time. 
Alternatively, knowledge that DMOG inhibits both FIH and PHD2 may suggest that dual and 
specific inhibition of these hydroxylases during de novo cartilage formation, may result in 
HIF-mediated transcription that is conducive for articular chondrogenesis. 
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Figure Titles & Legends 
 
Figure 1. Schematics highlighting the role of hydroxylase inhibitors in regulation of 
HIF-1α-mediated transcription and the study experimental design. 
(A) Under hypoxic conditions, HIF-1α forms an active transcription complex with HIF-1β 
and co-factors such as CBP/p300. This HIF complex then binds to the promoter regions of 
target genes at the HIF-response element sites, inducing transcription.  
 (B) At normoxia, two hydroxylases – PHD2 and FIH, utilise oxygen and other substrates to 
hydroxylate HIF-1α which promotes its degradation and inhibitis binding by CBP/p300. 
Here, we aimed to stabilise HIF-1α at normoxia by inhibiting the hydroxylases with CoCl2, 
DFX or DMOG. 
(C) Experiment design. To produce each biological replicate, hBM-MSCs were thawed and 
expanded to passage 5 before re-seeding at a density of 3x104 cell/cm2 in multi-well plates. 
Each well or set of wells was assigned to a specific condition: 20%O2, 20%O2+CoCl2, 
20%O2+DFX, 20%O2+DMOG or 5%O2. Separate experiments included each HIF-stabilising 
compound in the presence or absence of Acriflavine (ACF), and a comparison of late with 
constitutive exposure. In each condition, cultures were chondrogenically differentiated before 
assays at the time points specified in the legend of each figure. 
 
Figure 2. Hypoxia induces HIF-1α nuclear localisation and promotes an articular 
chondrocyte-like phenotype. 
(A+B) mRNA expression of VEGFA, EGLN and PGK1, and SOX9 (n=4) at day 1 (A) and 
SOX9, COL2A1 and COL10A1 (n=8) at day 14 of chondrogenesis (B). Values plotted are fold 
change in response to 5%O2 compared to 20%O2, which is represented by the horizontal 
dotted line. The solid grey line represents the mean. *denotes p<0.05 compared to 20%O2.  
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(C) hBM-MSC number throughout chondrogenesis as determined by PicoGreen assay (n=3). 
Values are normalised to cell number at day 0 and error bars show standard error of the mean. 
(D) Quantification of nuclear HIF-1α immunofluorescence in F-H at day 1 of chondrogenesis 
(n=3). Each value represents the percentage of a single nucleus that is occupied by HIF-1α. 
The red horizontal line represents the mean with *p<0.05 compared to 20%O2. 
(E-H) HIF-1α immunofluorescent staining. Scale Bar = 50μm. Representative images of 3 
independent repeats. Images were cropped and magnified to visualise localisation of HIF-1α.  
(I+J) Alcian Blue staining for GAGs with haematoxylin counterstain at day 21 of 
chondrogenesis (n=3). Scale bar = 400μm.  
(K-N) Collagen Type II (K+L) and X (M+N) immunofluorescence staining at day 21 of 
chondrogenesis (n=3). Scale bar = 400μm. Brightness and contrast were adjusted to an equal 
degree between all conditions.            
 
Figure 3. CoCl2, DFX and DMOG increase nuclear localisation of HIF-1α but only 
DMOG induces stable upregulation of HIF targets. 
(A+B) Detection of HIF-1α and housekeeping protein, β-Actin by Western Blot analysis of 
whole-cell lysates from hBM-MSCs at day 1 of chondrogenesis (A; n=4). Western blots were 
quantified and normalised to levels of β-Actin (B; n=4). Values are magnitude difference 
compared to the no treatment control, which is represented by the horizontal dotted line. 
Solid coloured lines are the mean for each condition. 
(C) Quantification of nuclear HIF-1α immunofluorescence at day 1 of chondrogenesis (n=4). 
Each value represents the percentage of a single nucleus that is occupied by HIF-1α. The red 
horizontal line represents the mean and *p<0.05 compared to 20%O2. 
(D-K) HIF-1α immunofluorescence staining at day 1 of chondrogenesis (n=4). Scale Bar = 
50μm. Images were cropped and magnified to visualise localisation of HIF-1α. Brightness 
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and contrast were adjusted to an equal degree between all conditions.   
(L-N) mRNA expression of VEGFA, PGK1 and EGLN due to CoCl2, DFX, DMOG and 
5%O2 (n=4). Values are fold change compared to the no treatment control represented by the 
horizontal dotted line. Solid coloured lines represent the mean for each condition. *p<0.05 
compared to 20%O2 at the same time point.  
 
Figure 4. DMOG induces a chondrogenic transcriptional profile and inhibits markers of 
osteoblastic and hypertrophic differentiation but also reduces the formation of a 
cartilage-like ECM. 
(A-J) mRNA expression of SOX9 (A; n=4), RUNX2 (B; n=4) and SOX9/RUNX2 (C; n=4), 
COL2A1 (D; n=7), COL10A1 (E; n=7), COL2A1/COL10A1 (F; n=7), ACAN (G; n=4), 
MMP13 (H; n=7), P4HA1 (I; n=4) and LOX (J; n=7) throughout chondrogenesis due to 
treatment with CoCl2, DFX, DMOG and 5%O2. Values are fold change compared to the no-
treatment control represented by the horizontal dotted line. Solid coloured lines are the mean 
for each condition. *p<0.05 compared to 20%O2 at the same time point.  
 
Figure 5. DMOG reduces the formation of a cartilage-like ECM. 
 (A-H) Collagen Type X (A-D) and II (E-H) immunofluorescence staining at day 21 of 
chondrogenesis (n=3). Scale bar = 400μm. Brightness and contrast were adjusted to an equal 
degree between all conditions. 
(I-L) Alcian Blue staining for GAGs with haematoxylin counterstain at day 21 of 
chondrogenesis (n=3). Scale bar = 400μm.  
(M+N) Quantification of Collagen Type II immunofluorescence (M) and 
Glycosaminoglycans (N) at day 21 of chondrogenesis (n=4) without (○/○/○) and with (●/●/●) 
normalisation to DAPI-immunofluorescence/double-stranded DNA. Values are fold change 
30 
 
compared to the no-treatment control represented by the horizontal dotted line. Solid 
coloured lines represent means for each condition. *p<0.05 compared to 20%O2. 
 
Figure 6. Inhibition of HIF-1α reduces the DMOG-mediated upregulation of a 
chondrogenic transcriptional profile  
(A-C) Collagen Type II immunofluorescence staining at day 14 of chondrogenesis. Scale bar 
= 400μm (n=4). Brightness and contrast were adjusted to an equal degree between all 
conditions. 
(D) Quantification of Collagen Type II immunofluorescence at day 14 of chondrogenic 
induction, normalised to equivalent DAPI-immunofluorescence (n=4). Values are fold 
change compared to the no-treatment control represented by the horizontal dotted line. 
Orange lines represent means for each condition. *p<0.05 compared to 20%O2. 
(E-J) mRNA expression of VEGFA (E) and EGLN (F), SOX9 (G), COL2A1 (H), COL10A1 
(I), and COL2A1/COL10A1 (J) at day 14 of chondrogenesis (n=4) after treatment with 
DMOG (●), 5%O2 (●), DMOG + Acriflavine (○) or 5%O2 + Acriflavine (○). Values are fold 
change compared to the no-treatment condition represented by the horizontal dotted line. 
Solid coloured lines represent means for each condition. *p<0.05 when compared to 20%O2, 
and #p<0.05 between +/-ACF conditions within 20%O2 + DMOG or 5%O2 groups.  
 
Figure 7. Late DMOG treatment does not inhibit the formation of a Collagen Type II-
rich ECM but does induce a chondrogenic expression profile. 
(A-G) Collagen Type II immunofluorescence staining at day 21 of chondrogenesis after 
continuous (days 1-21) and late (days 14-21) CoCl2, DFX and DMOG treatment (n=4). Scale 
bar = 400μm. Representative images from 4 independent repeats shown. Brightness and 
contrast were adjusted for all channels to an equal degree between all conditions. 
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(H) Quantification of Collagen Type II immunofluorescence at day 21 of chondrogenic 
induction, normalised to equivalent DAPI-immunofluorescence (n=4). Values are fold 
change compared to the no-treatment control represented by the horizontal dotted line. The 
horizontal, coloured lines represent means for each condition. *p<0.05 compared to 20%O2. 
(I-L) mRNA expression of SOX9 (I), P4HA1 (J), VEGFA (K) and EGLN (L) after continuous 
(days 1-21) and late (days 14-21) CoCl2, DFX and DMOG treatment (n=4). Values are 
normalised to the housekeeping gene RPL13A and are fold change compared to the no-
treatment control, represented by the horizontal dotted line. The horizontal coloured lines 
represent the means for each condition. *p<0.05 when compared to 20%O2.  
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Supplemental Figure 1. Primary antibody validation in hBM-MSC.  
(A, B, D, E, G, H) Immunofluorescence signal following immunostaining protocol in which 
the primary antibody was included.  
(C, F, I) Immunofluorescence signal following immunostaining protocol in which the 
primary antibody was omitted.  
(A-C) HIF-1α: 20%O2 (A) + 5%O2 (B+C) at day 1 of chondrogenesis. Scale bar = 100μm. 
(D-F) Collagen Type II: 20%O2 at days 0 (D) and 21 (E+F) of chondrogenesis. Scale bar = 
200μm. 
(G-I) Collagen Type X: 5%O2 (G) and 20%O2 (H+I) at day 21 of chondrogenesis. Scale bar 
= 200μm. 
 
Supplemental Figure 2. Determination of appropriate concentrations of CoCl2, DFX 
and DMOG that limit cell toxicity.   
(A-C) Cell viability throughout 21-day chondrogenic differentiation with varying 
concentrations of CoCl2 (A), DFX (B) and DMOG (C) included in the induction media. 
Values are normalised to cell number at day 0 and represent the mean of 3 independent 
repeats. Error bars show standard error of the mean. 
 
Supplemental Figure 3. Cell number in control, 5%O2-, CoCl2-, DFX- and DMOG-
treated cultures during chondrogenic differentiation of hBM-MSC.    
Cell number during the chondrogenic differentiation of hBM-MSC in the presence of CoCl2, 
DFX, DMOG or 5%O2. Values are normalised to cell number at day 0 and represent the 
mean of 3 independent repeats, with each repeat the mean of 3 technical replicates. Error bars 
show standard error of the mean. 
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Supplemental Figure 4. Effect of HIF-1α inhibition on mRNA expression of HIF target 
and chondrogenic genes. HIF-1α inhibition reduces DMOG’s effects more strongly than 
that induced by CoCl2, DFX or 5%O2.  
(A) Acriflavine (ACF) functional assay: Relative mRNA expression of HIF targets VEGF, 
EGLN, PGK1, and GLUT2 in control, DMOG-treated and DMOG+ACF treated cultures. 
ACF abolishes DMOG-mediated upregulation of HIF targets. Values plotted are magnitude 
difference compared to the 20%O2 condition. 
(B) Total cell number determined by DAPI fluorescence at day 14 of DMOG-mediated 
chondrogenic differentiation in presence of ACF. Values plotted are magnitude difference to 
that without ACF, which is represented by the dotted line. 
(C-H) mRNA expression levels represented in a heatmap of SOX9 (C), COL2A1 (D), LOX 
(E), MMP13 (F), COL10A1 (G), EGLN (H), and VEGFA (G) at day 14 of chondrogenesis 
after treatment with CoCl2, DFX, DMOG or 5%O2 in the absence and presence of Acriflavine 
(ACF). Values plotted are magnitude difference compared to untreated control within 
respective -ACF and +ACF groups and represent the mean from 4 independent experiments. 











Supplemental Table 1. qPCR Primer Sequences 
 
Gene of 
Interest 
Forward Primer Sequence Reverse Primer Sequence 
VEGFA AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA
PGK1 TGGACGTTAAAGGGAAGCGG GCTCATAAGGACTACCGACTTGG
EGLN AGGCGATAAGATCACCTGGAT TTCGTCCGGCCATTGATTTTG
SOX9 AGCGAACGCACATCAAGAC CTGTAGGCGATCTGTTGGGG
COL2A1 CCAGATGACCTTCCTACGCC TTCAGGGCAGTGTACGTGAAC
ACAN GTGCCTATCAGGACAAGGTCT GATGCCTTTCACCACGACTTC
RUNX2 TGGTTACTGTCATGGCGGGTA TCTCAGATCGTTGAACCTTGCTA
COL10A1 GGGGCTAAGGGTGAAAGGG GGTCCTCCAACTCCAGGATCA
MMP13 ACTGAGAGGCTCCGAGAAATG GAACCCCGCATCTTGGCTT
P4HA1 AGTACAGCGACAAAAGATCCAG CTCCAACTCACTCCACTCAGTA
LOX CGGCGGAGGAAAACTGTCT TCGGCTGGGTAAGAAATCTGA
RPL13A GCCATCGTGGCTAAACAGGTA GTTGGTGTTCATCCGCTTGC
 
